Multinationals oppose further decrease in Stent Prices by NPPA

Multinational companies such as Abbott, Medtronics, Meril Lifesciences and Boston Scientific were opposing control of stent prices on grounds that it will stifle access of innovative and advanced therapies for patients.

The Medical Technology Association of India (MTaI) - the lobby group of multinational or research-based medical devices companies have expressed disappointment over the government's decision.

"The decision is disappointing," said Pavan Choudary, Director General of MTaI reacting to NPPA's notification on stents prices.

"It will limit patient choice and the availability of innovative technologies in the market. The only saving grace in the order is NPPA's expression that it is open to receiving stakeholder views. Taking that in earnest, we will stay engaged," Choudary said.

A stent is a tiny expandable metal scaffold to open up narrowed or weakened arteries to ensure blood flow preventing heart attacks.

The price revision became imminent after the last year’s price cap order lapsed today.

NPPA last year’s February – has imposed pricing caps to bring down the prices of stents by as much as 85 percent under Schedule I of the DPCO, 2013 - citing to check unethical profiteering and exploitive pricing, and also to ensure fair, reasonable and affordable price for coronary stents.

2/17/2018 10:54:53 AM